ICON - One of World's Largest CRO'S - Selects Phase Forward for Electronic Data Capture (EDC).

ICON Inks Agreement Under Phase Forward's CRO Advantage Program

WALTHAM, Mass. -- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that ICON (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has signed an agreement with Phase Forward under its CRO Advantage Program. The agreement will enable ICON to offer their clients Phase Forward's market-leading electronic data capture (EDC) solution, InForm[TM].

Founded in 1990 in Dublin, Ireland, ICON has experienced significant growth, evolving into a globally acclaimed clinical research organization. The company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. These studies range from large, multinational trials to local, stand-alone projects.

"The new agreement will enable us to take advantage of Phase Forward's proven expertise in managing trials worldwide and the company's state of the art technology and strong global experience, which aligns well with our own expansion objectives," said Tom O'Leary, Global Head of Data Management, ICON. "Phase Forward's around-the-clock, multilingual technical support services staffed by in-house experts and the company's commitment to quality make it a significant addition to our partnership roster."

The partnership provides ICON's clients the option of using the InForm solution in trials managed by ICON. InForm's tangible benefits and the product's broad installed base have already contributed to several recent new business wins; ICON and Phase Forward jointly secured four separate clinical trial wins in the last quarter of 2006.

In addition to collaborating on new business opportunities, ICON's and Phase Forward's global business development and marketing teams are working side-by-side to share resources and expertise to best address customers' global business requirements.

"We look forward to working collaboratively on more joint business opportunities as ICON assists clients in accelerating and optimizing the clinical trial life cycle," said Bob Weiler, CEO and president, Phase Forward. "We are impressed with ICON's experienced team, which has built a worldwide reputation for excellence."

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm[TM]), clinical data management (Clintrial[TM]), clinical trials signal detection (CTSD[TM]), strategic pharmacovigilance (WebVDME[TM] and Signal Management), adverse event reporting (Clintrace[TM]) and applied data standards (WebSDM[TM]). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 260 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, Food and Drug Administration, GlaxoSmithKline, Merck, U.K. Medicines and Healthcare Products Regulatory Agency, National Institutes of Health, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Serono and Servier. Additional information about Phase Forward is available at www.phaseforward.com.

About ICON

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. ICON specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has over 4800 employees, operating from 48 locations in 30 countries. Further information is available at www.iconclinical.com.

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward's products and services, future business and operations plans of Phase Forward customers and partners, and the ability of Phase Forward's customers and partners to realize benefits from the use of Phase Forward's products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers and partners to realize benefits from the use of its products and services, changes in regulatory requirements applicable to Phase Forward's customers and partners, the manner in which Phase Forward's customers and partners conduct business and the possibility that their needs or plans may change over time, and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Quarterly Report on Form 10-Q.